StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.
Pieris Pharmaceuticals Stock Performance
NASDAQ PIRS opened at $15.59 on Tuesday. The company has a market cap of $20.58 million, a PE ratio of -1.29 and a beta of 0.66. The firm’s 50 day moving average price is $16.57 and its 200-day moving average price is $13.83. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned about 1.21% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by institutional investors and hedge funds.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Recommended Stories
- Five stocks we like better than Pieris Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
